Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Month Open-Label, Repeat-Dose Safety Study of NRL-1 in Epilepsy Subjects (DIAZ.001.05)

NCT02721069 is registered in ClinicalTrials.gov with Neurelis, Inc. as lead sponsor.

NCT NCT02721069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02721069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Month Open-Label, Repeat-Dose Safety Study of NRL-1 in Epilepsy Subjects (DIAZ.001.05)
Lead sponsor
Neurelis, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 11, 2016
Completion date
July 23, 2020
Enrollment
175 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute repetitive seizures, breakthrough seizures